Iroko gets a thumbs-up from FDA on lower-dose NSAID

Iroko Pharmaceuticals failed to launch a $145 million IPO earlier in the year, but it has managed to win regulatory approval for a lower-dose, nonsteroidal anti-inflammatory drug--Zorvolex--which promises to ease mild to moderate levels of pain with a lower risk to patients. Higher doses of NSAIDs have been linked to strokes, gastrointestinal ulcers and acute renal failures. Story

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.